Olmesartán Alter (Olmesartan Medoxomil)

Olmesartan medoxomil acts on the renin‑angiotensin system to manage arterial hypertension and related conditions.

• Essential hypertension: reduces systolic and diastolic blood pressure to target levels.
• Hypertension with type 2 diabetes: helps control blood pressure and may protect renal function.
• Hypertension in chronic kidney disease: lowers blood pressure while supporting kidney health.

• Olmesartan medoxomil selectively blocks the binding of angiotensin II to the AT1 receptor on vascular smooth muscle and adrenal glands. This inhibition prevents vasoconstriction and aldosterone secretion, leading to vasodilation, reduced peripheral resistance, and decreased blood pressure.

Olmesartan medoxomil may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects

• Dizziness: light‑headed sensation, especially after standing.
• Headache: mild to moderate pain in the head region.
• Fatigue: feeling unusually tired or weak.
• Nasal congestion: blocked or runny nose.
• Diarrhea: loose stools occurring intermittently.
• Cough: dry, non‑productive throat irritation.

Serious or Rare Side Effects

• Angioedema: swelling of the face, lips, tongue, or throat requiring urgent care.
• Hyperkalemia: elevated potassium levels that may affect heart rhythm.
• Acute renal failure: sudden decline in kidney function.
• Severe hypotension: markedly low blood pressure causing fainting.
• Liver enzyme elevation: increased ALT/AST indicating hepatic stress.
• Myocardial infarction: rare occurrence of heart attack symptoms.

Before initiating therapy with Olmesartan medoxomil, several safety considerations should be observed.

• Blood pressure monitoring: ensure adequate control and avoid excessive drops.
• Renal function assessment: evaluate serum creatinine and eGFR periodically.
• Electrolyte balance: check potassium levels, especially if combined with potassium‑sparing agents.
• Pregnancy avoidance: contraindicated in the second and third trimesters due to fetal risk.
• Elderly caution: start at lower doses and monitor for orthostatic hypotension.
• Store at ambient temperature: keep in the original container, protect from moisture and direct sunlight.

Olmesartan medoxomil can interact with several medicines, influencing its efficacy or safety profile.

Major Interactions (Avoid)

• ACE inhibitors or other ARBs: combined use may cause additive hypotension and renal impairment.
• Potassium‑sparing diuretics or supplements: increase risk of hyperkalemia.
• Lithium: may raise lithium concentrations, leading to toxicity.
• NSAIDs (e.g., ibuprofen, naproxen): can blunt antihypertensive effect and affect renal function.
• Aliskiren (in diabetic patients): heightened risk of adverse renal outcomes.

Moderate Interactions (Monitor Closely)

• Thiazide diuretics: may enhance blood‑pressure‑lowering effect, requiring dose adjustment.
• CYP450 inhibitors (e.g., ketoconazole): could modestly increase olmesartan levels.
• Other antihypertensives (beta‑blockers, calcium channel blockers): monitor for excessive hypotension.
• Antacids containing aluminum or magnesium: may reduce absorption if taken simultaneously.